[C5: eculizumab].

Katsuichi, Miyamoto

Found an issue? Give us feedback

https://pubmed.ncbi....arrow_drop_down

https://pubmed.ncbi.nlm.nih.go...

Article . 2015

Data sources: Europe PubMed Central

[C5: eculizumab].

descriptionPublicationkeyboard_double_arrow_right Article 20 Jan 2015 Japanese Journal:Brain and nerve = Shinkei kenkyu no shinpo, volume 66 (issn: 1881-6096,

Copyright policy )

Authors: Katsuichi, Miyamoto;

pmid: 25296873

[C5: eculizumab].

- Summary
- Subjects
- Metrics

Abstract

Eculizumab is a recombinant humanized monoclonal antibody that specifically binds to a C5 terminal complement and inhibits the cleavage of C5 to C5a and C5b through complement activation. Eculizumab has been used clinically for paroxysmal nocturnal hemoglobinuria. Clinical studies have been initiated for neurological disorders, such as, optic neuromyelitis and myasthenia gravis, mediated by the complement system. In addition, eculizumab is expected to be useful for the treatment of intractable neurological diseases.

Related Organizations

Kindai University
Japan

Keywords

Myasthenia Gravis, Neuromyelitis Optica, Hemoglobinuria, Paroxysmal, Animals, Complement C5, Humans, Molecular Targeted Therapy, Antibodies, Monoclonal, Humanized

Impact byBIP!

	citations The total number of citations received by all articles of the researcher of interest.	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average